My name is Emily. I’m a 26-year-old from Washington, D.C., and I live with psoriatic arthritis.
NEW REPORT: Big Pharma’s Lockstep Price Hikes On Widely Used Blood Thinners Exploit Patients And Taxpayers
A new report issued today documents how drug companies use their market and political power to avoid competition and raise prices in lockstep.
This report examines the practices of BMS/Pfizer and Johnson & Johnson's lockstep price hikes and patent gaming on two blockbuster blood thinners and the implications for patients and taxpayers.
Since P4AD’s initial report in mid-January, drug companies have increased the price of 188 more drugs, bringing the total to 742 hikes so far this year.
Drug companies raised the prices of 742 drugs in January 2022
The report demonstrates why urgent congressional action is needed to address Big Pharma’s abusive pricing practices.